AOD-9604 has an unusually well-documented history for a research-chemical peptide: it was actually developed and tested as a pharmaceutical candidate, and that development history tells you a lot about where the evidence currently stands.
What It Is
AOD-9604 is a synthetic fragment of human growth hormone, specifically the region researchers believed was responsible for growth hormone's fat-metabolizing effects without its growth-promoting effects, developed with the specific goal of separating those two actions.
Regulatory and Development History
AOD-9604 was developed by an Australian biotechnology company and went through Phase 2 clinical trials as a potential obesity treatment in the 2000s. It did not proceed to Phase 3 trials or reach approval, as the sponsoring company's own reported trial results did not demonstrate the level of efficacy needed to justify continued development as a weight-loss drug. It is not FDA-approved and is currently sold as a research chemical.
What the Research Shows
Unlike many compounds on this site, AOD-9604 does have a documented human Phase 2 trial behind it, which is more clinical testing than most research-chemical peptides receive. That trial's own outcome, insufficient efficacy to continue development, is directly relevant context that's frequently left out of current marketing, which instead often cites the earlier, more promising preclinical and animal research that motivated the trial in the first place.
Safety Considerations
The Phase 2 trial that was conducted did not reportedly identify major safety concerns at studied doses, which is a genuinely more substantial safety signal than exists for most unapproved research peptides. However, this doesn't extend to the different, often much higher or more frequent, doses and combination protocols commonly promoted in current research-chemical marketing, which weren't the doses actually studied.
The Bottom Line
AOD-9604 is a useful, concrete example of a peptide that was actually tested in humans specifically for the effect it's still marketed for today, weight loss, and found insufficiently effective to warrant continued pharmaceutical development. That history is directly relevant and worth knowing before evaluating any current marketing claims about it.
What the Discontinuation Actually Tells You
It's worth being direct about what a discontinued Phase 2 program signals: pharmaceutical companies don't abandon a promising, well-funded drug candidate lightly, given how much has already been invested by that stage. A decision to stop development after Phase 2, rather than continuing to Phase 3, generally reflects the sponsor's own assessment that the trial data didn't support continued investment, a more informative signal about likely real-world efficacy than the absence of any trial data at all would be.